Compare NetEase Inc (NTES) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Novartis AG — how do they compare? NetEase Inc trades at $124.24 (market cap $76.09B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 3.5× NetEase Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 73 Days and Novartis AG for 82 Days on average.
| NTES | NVS | |
|---|---|---|
Market Cap | $76.09B | $268.57B |
Volume | 486,447 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $152.85 | $168.62 |
52-Week Low | $109.26 | $121.80 |
Typical Hold Time | 73 Days | 82 Days |
Enterprise Value | $51.81B | $309.89B |
Dividend Yield | 2.45% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $119.60, down 0.84% with neutral technical signals. The company maintains strong fundamentals with $112.63B revenue and 27.88% net margin in 2025, though recent quarterly earnings show mixed results with two misses and one beat. Analyst consensus remains strongly bullish with 82% buy ratings and $168 price target, representing 40% upside potential from current levels.
NTES presents compelling value with reasonable P/E of 15.9 and strong cash flow generation, but faces execution risks from inconsistent earnings performance and competitive pressures in gaming. The stock's current valuation discount to analyst targets offers opportunity, though investors should monitor Q3 2026 results for sustained growth trajectory.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
